Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primaquine therapy for malaria.

J Kevin Baird1, Stephen L Hoffman

  • 1US Naval Medical Research Center Detachment, Lima, Peru. bairdk@nmrc.navy.mil

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of higher dose primaquine for the radical cure of <i>Plasmodium vivax</i> malaria in Indonesia: a systematic review and individual patient data meta-analysis.

The Lancet regional health. Western Pacific·2026
Same author

Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections.

PLoS pathogens·2026
Same author

Molecular detection and genetic characterisation of a large flood-borne outbreak of human leptospirosis in Jakarta, Indonesia: A retrospective analysis of surveillance data.

PLoS neglected tropical diseases·2026
Same author

Correction: Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression.

PLoS pathogens·2026
Same author

G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination.

The Lancet regional health. Western Pacific·2026
Same author

Invisible Malarias.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Primaquine is crucial for preventing malaria relapse. A 14-day regimen of 0.5 mg/kg daily is recommended for efficacy and safety in eligible individuals, addressing concerns about resistance.

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Primaquine is the sole drug available for preventing malaria relapse.
  • Significant confusion exists regarding optimal primaquine usage and efficacy.
  • Plasmodium vivax malaria relapse rates vary widely by geographic location (5-80%+).

Purpose of the Study:

  • To review the clinical applications of primaquine in malaria treatment from 1946 to 2004.
  • To assess the efficacy and safety of different primaquine dosing regimens.
  • To provide evidence-based recommendations for primaquine therapy.

Main Methods:

  • Comprehensive literature review of clinical studies on primaquine.
  • Analysis of relapse rates associated with geographic location and therapy supervision.

Related Experiment Videos

  • Evaluation of reported primaquine resistance and treatment outcomes.

    • Main Results:

    • Lack of therapy supervision is linked to most primaquine resistance reports.
    • The standard 14-day regimen (15 mg daily) may face widespread resistance.
    • A 5-day regimen (15 mg daily) shows no discernible efficacy.
    • A 14-day regimen of 0.5 mg/kg daily demonstrates superior efficacy and safety.

    Conclusions:

    • A 14-day regimen of 0.5 mg/kg primaquine daily is recommended for preventing malaria relapse.
    • This regimen is well-tolerated and safe in non-pregnant individuals without G6PD deficiency.
    • Addressing primaquine resistance requires adherence to effective treatment protocols.